Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE -321.8%. (2020–2024 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Market Cap | $15M | — | — | — | — | — |
| Enterprise Value | $25M | — | — | — | — | — |
| P/E Ratio → | -0.04 | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — |
| P/B Ratio | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| ROE | -321.8% | -321.8% | -99.1% | -66.6% | -91.7% | -15.3% |
| ROA | -207.8% | -207.8% | -79.9% | -55.5% | -82.7% | -14.1% |
| ROIC | -22.4% | -22.4% | -65.9% | -47.9% | -75.1% | -10.9% |
| ROCE | -33.2% | -33.2% | -90.7% | -61.5% | -87.3% | -12.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.03 | 0.12 | 0.10 | 0.04 |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | — | 0.03 | 0.08 | -0.03 | -0.08 |
| Net Debt / EBITDA | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | -244.30 | -244.30 | -35.32 | -55.13 | -303.24 | -69.73 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Current Ratio | 0.04 | 0.04 | 0.07 | 0.23 | 1.48 | 11.08 |
| Quick Ratio | 0.04 | 0.04 | 0.07 | 0.23 | 1.48 | 11.08 |
| Cash Ratio | 0.02 | 0.02 | 0.01 | 0.17 | 1.42 | 10.96 |
| Asset Turnover | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | — | — | — | — | — |
| Shares Outstanding | — | $2M | $1M | $703317 | $656600 | $589591 |
Imminent insolvency and dilution
As reported in recent financial statements, LNAI's net margin of -122.8% in 2025Q3 highlights a profound inability to generate earnings, with the company's cost structure remaining entirely disconnected from any meaningful revenue generation, leaving the firm in a state of persistent and deepening operational loss.
The gross margin of 47.5% appears misleadingly high for a pre-revenue entity, likely reflecting accounting anomalies rather than true product profitability. Investors should monitor the widening operating margin, which suggests that the company's pivot to AI-driven therapeutics has yet to yield any efficiency gains or cost rationalization.
Based on reported figures, LNAI's asset turnover ratio of 0.00 in 2025Q3 confirms the absence of productive commercial activity, while the lack of meaningful inventory or receivables turnover metrics underscores a business model that has yet to transition from theoretical development to operational execution.
The absence of a functional cash conversion cycle indicates that the company is not managing working capital in a traditional sense, but rather consuming cash to sustain administrative overhead. This lack of operational velocity suggests that the firm is not yet a viable commercial enterprise.
According to the most recent quarterly data, LNAI's current ratio of 0.19 indicates a severe liquidity crisis, as the company's cash reserves are insufficient to cover even a fraction of its near-term liabilities, leaving the firm highly vulnerable to immediate insolvency without external capital injections.
The quick ratio, identical to the current ratio at 0.19, confirms that the company lacks any liquid assets to buffer against its ongoing cash burn. This liquidity position warrants extreme caution, as it suggests the company is operating on a day-to-day basis with no margin for error.
As indicated by historical filings, the market's tendency to apply standard biotech valuation multiples to LNAI is fundamentally flawed, as the company's frequent corporate identity shifts and lack of clinical-stage assets render traditional P/E or EV/EBITDA metrics entirely irrelevant for assessing its true intrinsic value.
Investors should instead focus on the cash-to-burn ratio and the probability of successful IND filings, as these are the only metrics that reflect the company's actual survival prospects. Relying on standard valuation multiples obscures the reality that the company is currently a distressed entity rather than a growth-stage biotech firm.
Includes 30+ ratios · 5 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying LNAI stock.
Lunai Bioworks Inc.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
Lunai Bioworks Inc.'s return on equity (ROE) is -321.8%. The historical average is -118.9%.
Based on historical data, Lunai Bioworks Inc. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.